Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | +45.11% | +4.68% | +9.53% | +15.48% | +21.54% | +43.03% | +60.27% | +91.02% | +153.84% | +163.86% | +350.28% | +350.28% |
| FP HCARE-A | +18.43% | +3.05% | +6.91% | +11.87% | +10.85% | +22.06% | +26.43% | +34.62% | +37.39% | +92.49% | +102.03% | +102.03% |
| SCBRMGHC | +10.03% | +2.73% | +5.09% | +7.13% | +4.42% | +13.92% | +19.29% | +44.16% | +20.54% | +71.47% | +126.86% | +126.86% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes AMGN: money market or bond funds, or no holdings data yet
| FP HCARE-A | SCBRMGHC | |
|---|---|---|
| Held by both | ||
 Eli Lilly and Co | 8.91% | 9.53% |
 Johnson & Johnson | 7.53% | 7.71% |
 ABBVIE | 5.39% | 4.89% |
 AstraZeneca | 4.94% | 3.68% |
 Thermo Fisher | 3.16% | 3.32% |
 Roche | 3.51% | 2.66% |
| Only in FP HCARE-A | ||
 Amgen | 5.67% | N/A |
 Medtronic | 3.94% | N/A |
 McKesson | 3.10% | N/A |
 GSK | 2.99% | N/A |
| Only in SCBRMGHC | ||
 Unitedhealth Group | N/A | 4.23% |
 Novartis | N/A | 2.71% |
 argenx | N/A | 2.43% |
 Merck & | N/A | 2.33% |
30 Dec 2025 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| AMGN | +45.11% | 29.53% | 1.53 |
| FP HCARE-A | +18.43% | 16.53% | 1.11 |
| SCBRMGHC | +10.03% | 16.76% | 0.60 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | AMGN | FP HCARE-A | SCBRMGHC |
|---|---|---|---|
Fund details | |||
| Fund size | N/A | 28.56 million | 2,408 million |
| Inception date | N/A | 18 Aug 2014 | 6 Nov 2015 |
| Master fund | N/A | Manulife Global Fund – Healthcare Fund | Janus Henderson Global Life Sciences Fund |
| Dividend policy | N/A | Does not pay | Does not pay |
Risk and currency hedging | |||
| Risk level | N/A | 7 | 7 |
| Hedging policy | N/A | Hedged at the manager's discretion | Almost fully hedged |
| Share hedged | N/A | 14.65% | 99.36% |
Minimum purchase and redemption | |||
| First purchase | N/A | 1,000 THB | 1,000 THB |
| Subsequent purchase | N/A | No minimum | 1,000 THB |
| Redemption (amount) | N/A | No minimum | 1,000 THB |
| Redemption (units) | N/A | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | 1,000 THB |
| Balance (units) | N/A | No minimum | No minimum |
Order cut-off and redemption payment | |||
| Buy before | N/A | 15:30 | 15:30 |
| Redeem before | N/A | 15:30 | 15:30 |
| Redemption paid | N/A | T+5 | T+5 |
